Phyteau

Developing a new class of completely safe therapeutics for diabetes, obesity, metabolism and weight-loss.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Santa Fe, NM, USA
  • Currency USD
  • Founded July 2017
  • Employees 3
  • Incorporation Type C-corp
  • Website phyteau.co

Company Summary

Phyteau is developing a new class of therapeutics for diabetes, obesity, weight-loss & related conditions. We're creating next generation incretin therapy.

We target specialized metabolic cells in the intestines triggering them to therapeutically boost the release of key incretin & metabolic hormones: GLP-1, PYY, OXM, CCK. The result is a range of superior, safe, affordable applications in pharmaceuticals and consumer health & medical nutrition.

Team

  • Bonn Macy
    CEO

    B.S., M.S. Columbia University, M.Sc. London School of Economics. Ex- McKinsey and Booz Allen. 20+ years in strategy, planning, market, management and tech commercialization.

  • Stephen Pandol, M.D.
    Chief Medical Officer

    Prof. of Medicine, UCLA; Director, Translational Pancreatic research, Cedars Sinai Medical Center.

  • Janine Lehmann
    Product Director

    B.A. Hunter College, City of New York. Co-Founder of 2 startups. Expertise in operations, advertising, marketing and design.

Advisors

Previous Investors

  • SOSV
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free